Goldie Y.L. Lui

1.2k total citations
17 papers, 872 citations indexed

About

Goldie Y.L. Lui is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Goldie Y.L. Lui has authored 17 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Hematology. Recurrent topics in Goldie Y.L. Lui's work include Mechanisms of cancer metastasis (5 papers), Cancer Mechanisms and Therapy (3 papers) and Iron Metabolism and Disorders (3 papers). Goldie Y.L. Lui is often cited by papers focused on Mechanisms of cancer metastasis (5 papers), Cancer Mechanisms and Therapy (3 papers) and Iron Metabolism and Disorders (3 papers). Goldie Y.L. Lui collaborates with scholars based in Australia, United States and United Kingdom. Goldie Y.L. Lui's co-authors include Des R. Richardson, Žaklina Kovačević, Danuta S. Kalinowski, Christopher J. Kemp, Carla Grandori, Sherin Chikhani, Angelica M. Merlot, Sutharshani Sivagurunathan, Věra Richardson and Danae M. Sharp and has published in prestigious journals such as Cancer Research, Oncogene and Free Radical Biology and Medicine.

In The Last Decade

Goldie Y.L. Lui

17 papers receiving 862 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Goldie Y.L. Lui Australia	12	523	316	165	143	126	17	872
Samuel Seoane Spain	18	492 0.9×	361 1.1×	91 0.6×	60 0.4×	33 0.3×	38	1.1k
Ota Fuchs Czechia	18	569 1.1×	164 0.5×	111 0.7×	444 3.1×	82 0.7×	67	1.0k
Teeru Bihani United States	14	530 1.0×	388 1.2×	353 2.1×	44 0.3×	40 0.3×	27	1.1k
Gretchen M. Unger United States	17	1.2k 2.3×	438 1.4×	83 0.5×	85 0.6×	33 0.3×	29	1.6k
Clifton Stephens United States	16	515 1.0×	256 0.8×	100 0.6×	57 0.4×	30 0.2×	23	966
Laura G.M. Daenen Netherlands	14	612 1.2×	679 2.1×	192 1.2×	57 0.4×	44 0.3×	30	1.3k
Gennaro Colella Italy	16	800 1.5×	439 1.4×	94 0.6×	106 0.7×	16 0.1×	29	1.1k
Bedrich L. Eckhardt United States	19	741 1.4×	626 2.0×	156 0.9×	45 0.3×	68 0.5×	26	1.5k
Nen C. Pagano United States	5	840 1.6×	245 0.8×	575 3.5×	47 0.3×	74 0.6×	8	1.1k
Jacqueline M. Greer United States	15	756 1.4×	418 1.3×	94 0.6×	614 4.3×	28 0.2×	33	1.2k

Countries citing papers authored by Goldie Y.L. Lui

Since Specialization

Citations

This map shows the geographic impact of Goldie Y.L. Lui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Goldie Y.L. Lui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Goldie Y.L. Lui more than expected).

Fields of papers citing papers by Goldie Y.L. Lui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Goldie Y.L. Lui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Goldie Y.L. Lui. The network helps show where Goldie Y.L. Lui may publish in the future.

Co-authorship network of co-authors of Goldie Y.L. Lui

This figure shows the co-authorship network connecting the top 25 collaborators of Goldie Y.L. Lui. A scholar is included among the top collaborators of Goldie Y.L. Lui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Goldie Y.L. Lui. Goldie Y.L. Lui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Shigeta, Shogo, Goldie Y.L. Lui, Reid Shaw, et al.. (2021). Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Molecular Cancer Therapeutics. 20(4). 691–703. 22 indexed citations

Beaumont, Kimberley A., Danae M. Sharp, Goldie Y.L. Lui, et al.. (2020). Abrogation of RAB27A expression transiently affects melanoma cell proliferation. Pigment Cell & Melanoma Research. 33(6). 889–894. 6 indexed citations

Lui, Goldie Y.L., Reid Shaw, Franz X. Schaub, et al.. (2020). BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. EBioMedicine. 60. 102988–102988. 26 indexed citations

Guo, Dandan, Goldie Y.L. Lui, James S. Wilmott, et al.. (2019). RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes. Experimental Dermatology. 28(3). 6 indexed citations

Cao, Joan, Zhou Zhu, Hui Wang, et al.. (2019). Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer. Oncogene. 38(21). 4125–4141. 30 indexed citations

Lui, Goldie Y.L., Carla Grandori, & Christopher J. Kemp. (2018). CDK12: an emerging therapeutic target for cancer. Journal of Clinical Pathology. 71(11). 957–962. 90 indexed citations

Beaumont, Kimberley A., David S. Hill, Goldie Y.L. Lui, et al.. (2016). Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. Journal of Investigative Dermatology. 136(7). 1479–1489. 48 indexed citations

Lui, Goldie Y.L., Žaklina Kovačević, Věra Richardson, et al.. (2015). Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget. 6(22). 18748–18779. 138 indexed citations

Lui, Goldie Y.L., Žaklina Kovačević, Sharleen V. Menezes, et al.. (2015). Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6–Induced Activation by Iron Depletion. Molecular Pharmacology. 87(3). 543–560. 41 indexed citations

10.

Wei, Ping, Ming Qiu, Nathan Lee, et al.. (2015). Abstract 764: Rational combination of PF-06463922 (next-generation ALK inhibitor) with PI3K pathway inhibitors overcomes ALKi resistance in EML4-ALK+ NSCLC models. Cancer Research. 75(15_Supplement). 764–764. 4 indexed citations

11.

Felip, Enriqueta, D. Kim, Ranee Mehra, et al.. (2014). Efficacy and Safety of Ceritinib in Patients (Pts) with Advanced Anaplastic Lymphoma Kinase (Alk)-Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc): an Update of Ascend-1. Annals of Oncology. 25. iv456–iv456. 32 indexed citations

12.

Lui, Goldie Y.L., Žaklina Kovačević, Yao Mu, et al.. (2013). Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer. 108(2). 409–419. 97 indexed citations

13.

Kovačević, Žaklina, Sherin Chikhani, Goldie Y.L. Lui, Sutharshani Sivagurunathan, & Des R. Richardson. (2012). The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants and Redox Signaling. 18(8). 874–887. 145 indexed citations

14.

Lui, Goldie Y.L., Peyman Obeidy, Samuel Ford, et al.. (2012). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology. 83(1). 179–190. 115 indexed citations

15.

Ford, Samuel, Peyman Obeidy, Matthew Bedford, et al.. (2012). Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo. British Journal of Pharmacology. 168(6). 1316–1328. 70 indexed citations

16.

Kovačević, Žaklina, et al.. (2012). A new strategy for the treatment of pancreatic cancer: Novel thiosemicarbazone iron chelators that up-regulate the iron-regulated metastasis suppressor, NDRG1. Free Radical Biology and Medicine. 53. S121–S122. 1 indexed citations

17.

Lui, Goldie Y.L., Katie M. Dixon, Žaklina Kovačević, et al.. (2012). 379 The Anti-tumor Agent, Dp44mT, Differentially Targets the AKT, TGF-beta and ERK Pathways Via the Metastasis Suppressor NDRG1 in Normal Prostate Epithelial Cells and Prostate Cancer Cells. European Journal of Cancer. 48. 115–116. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact